Amylyx Pharmaceuticals, Inc.
AMLXFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Amylyx Pharmaceuticals, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Source: Amylyx Pharmaceuticals, Inc. — 10-K filed Mar 3, 2026
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 5 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 8, 2026.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Amylyx Pharmaceuticals, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2024-09-03 · MILNE GEORGE M JR: Larger than all 9 other insider purchases of Common Stock on file. SEC filing
Independent insiders buying near the same time
- 2024-09-05–2024-09-12: 2 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing )
- 2024-09-03–2024-09-05: 2 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing )
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-05-21 | Firestone Karen · Director | Common Stock | P — Open market or private purchase | +3,800 | 13.51 | SEC filing |
| 2026-03-02 | Bedrosian Camille L · Chief Medical Officer | Common Stock | S — Open market or private sale | −6,461 | 14.58 | SEC filing |
| 2026-03-02 | Cohen Joshua B · Co-Chief Executive Officer | Common Stock | S — Open market or private sale | −29,282 | 14.48 | SEC filing |
| 2026-03-02 | Klee Justin B. · Co-Chief Executive Officer | Common Stock | S — Open market or private sale | −29,282 | 14.47 | SEC filing |
| 2026-03-02 | FRATES JAMES M · Chief Financial Officer | Common Stock | S — Open market or private sale | −7,909 | 14.52 | SEC filing |
| 2026-03-02 | Mazzariello Gina · Chief Legal Officer | Common Stock | S — Open market or private sale | −6,844 | 14.52 | SEC filing |
| 2026-02-23 | Mazzariello Gina · Chief Legal Officer | Common Stock | S — Open market or private sale | −3,419 | 14.14 | SEC filing |
| 2026-02-02 | Mazzariello Gina · Chief Legal Officer | Common Stock | S — Open market or private sale | −3,448 | 14.65 | SEC filing |
Showing 8 of 20 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-04 | MILNE GEORGE M JR · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +24,372 | SEC filing |
| 2026-06-04 | Firestone Karen · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +24,372 | SEC filing |
| 2026-06-04 | Zeiher Bernhardt G · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +24,372 | SEC filing |
| 2026-06-04 | Quimi Daphne · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +24,372 | SEC filing |
| 2026-06-04 | FONTEYNE PAUL R. · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +24,372 | SEC filing |
| 2026-03-05 | Mazzariello Gina · Chief Legal Officer | Common Stock | A — Grant, award, or other acquisition | +74,660 | SEC filing |
| 2026-03-05 | Cohen Joshua B · Co-Chief Executive Officer | Common Stock | A — Grant, award, or other acquisition | +248,865 | SEC filing |
| 2026-03-05 | Klee Justin B. · Co-Chief Executive Officer | Common Stock | A — Grant, award, or other acquisition | +248,865 | SEC filing |
Showing 8 of 30 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.